title: The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation.
abstract: Objective. Systemic lupus erythematosus (SLE) is an autoimmune disease identified by a plethora of production of autoantibodies. Autoreactive T cells may play an important role in the process. Attenuated T cell vaccination (TCV) has proven to benefit some autoimmune diseases by deleting or suppressing pathogenic T cells. However, clinical evidence for TCV in SLE is still limited. Therefore, this self-controlled study concentrates on the clinical effects of TCV on SLE patients.Methods. 16 patients were enrolled in the study; they accepted TCV regularly. SLEDAI, clinical symptoms, blood parameters including complements 3 and 4 levels, ANA, and anti-ds-DNA antibodies were tested. In addition, the side effects and drug usage were observed during the patients' treatment and follow-up.Results. Remissions in clinical symptoms such as facial rash, vasculitis, and proteinuria were noted in most patients. There are also evident reductions in SLEDAI, anti-ds-DNA antibodies, and GC dose and increases in C3 and C4 levels, with no pathogenic side effects during treatment and follow-up.Conclusions. T cell vaccination is helpful in alleviating and regulating systemic lupus erythematosus manifestation.
authors.affiliation: Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China; West China School of Public Health, No. 4 West China Teaching Hospital, Sichuan University, Chengdu, China.
authors.forename: Liuye
authors.initials: L
authors.lastname: Huang
authors.affiliation: Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China.
authors.forename: Yuan
authors.identifier: 0000-0002-1909-0064
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Kuang
authors.affiliation: Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China.
authors.forename: Dapeng
authors.initials: D
authors.lastname: Wei
authors.affiliation: Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China.
authors.forename: Wanyi
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Rheumatology, Jinjiang District People's Hospital of Chengdu City, Chengdu, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Yin
authors.affiliation: West China School of Public Health, No. 4 West China Teaching Hospital, Sichuan University, Chengdu, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Pang
authors.affiliation: ICU, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Zhongwei
authors.identifier: 0000-0001-6720-2406
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D003176:Complement C3 / Q000276:immunology; D003181:Complement C4 / Q000276:immunology; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*; D055815:Young Adult
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D003176:Complement C3; D003181:Complement C4; D006886:Hydroxychloroquine; D009173:Mycophenolic Acid; D008727:Methotrexate